deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT01814813

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)

Sponsor: Agenus Inc.

Conditions Gliosarcoma Recurrent Adult Brain Tumor Recurrent Glioblastoma
Interventions HSPPC-96 bevacizumab
Updated 16 times since 2017 Last updated: Jan 13, 2025 Started: Jun 19, 2013 Primary completion: Apr 3, 2017 Completion: May 22, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

DSMB futility analysis

Other terminated trials from Agenus Inc.

More terminations from Agenus Inc.

Listed as NCT01814813, this PHASE2 trial focuses on Gliosarcoma and Recurrent Adult Brain Tumor and remains terminated or withdrawn. Sponsored by Agenus Inc., it has been updated 16 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Nov 2017 · 8 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Jul 2019 · 13 months · monthly snapshot~Jul 2019 – ~Aug 2020 · 13 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2022 · 15 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jun 2023 · 5 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Feb 2025 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Feb 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Jun 2023 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

▶ Show 11 earlier versions

  1. Jan 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2021 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Jul 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Jun 2018 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Nov 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Mar 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Agenus Inc.
  • Alliance for Clinical Trials in Oncology
  • National Cancer Institute (NCI)
Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Adrian, United States , Allentown, United States , Anaconda, United States , Anacortes, United States , Anchorage, United States , Ann Arbor, United States , Antioch, United States , Atlanta, United States , Auburn, United States and 254 more locations